{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:49:57Z","timestamp":1782190197066,"version":"3.54.5"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although next-generation sequencing (NGS) has been widely used to provide comprehensive somatic mutational information for individualized therapy in breast cancer patients, whether or not it could reliably evaluate HER2 status to guide targeted therapy when compared to the current IHC\/FISH standard criteria still lacks sufficient validations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the clinicopathological and NGS somatic genomic data of 1,171 Chinese breast cancer patients. A commercial 520 gene panel was used to generate genomic variation data by NGS in breast cancer samples. We compared the concordance of HER2 status between NGS evaluation and IHC\/FISH criteria. We further defined the amplification status of HER2 based on the length of amplification region beginning from ERBB2 and extending to adjacent genes by focal (&amp;lt;1 megabase) versus broad (&amp;gt;1 megabase) amplification and stratified the cohort accordingly to investigate its potential in predicting efficacy of trastuzumab-based neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NGS showed high concordance with FISH\/IHC-defined HER2 status with a sensitivity of 95.7%, specificity of 94.2%, and overall concordance rate of 94.9%. NGS characterized the genomic landscape of enrolled patients, identifying frequent mutations including TP53, ERBB2, PIK3CA, CDK12, MYC, and CCND1. The focal amplification subgroup exhibited significantly higher gene copy number (GCN) (31.7 vs 10.2, p &amp;lt; 0.001), greater HER2 positivity rates (98.3% vs. 78.3%, p &amp;lt; 0.001), higher IHC 3+ prevalence (91.7% vs. 48.5%, p &amp;lt; 0.001) and increased FISH + proportion (98.5% vs. 77.9%, p &amp;lt; 0.001). In patients receiving HER2-targeted neoadjuvant therapy, the focal amplification group had a higher pCR rate compared with broad amplification group (46.0% vs. 20.0%, p = 0.031).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NGS demonstrates comparable capability to IHC\/FISH in HER2 status interpretation and provides additional genomic information. Higher HER2 NGS copy numbers and focal amplification may be associated with a higher pCR rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1873228","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:29:34Z","timestamp":1782188974000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of HER2 status and characteristics by next-generation sequencing in breast cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Nanqiu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]},{"name":"Shantou University Medical College","place":["Shantou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinze","family":"Lv","sequence":"additional","affiliation":[{"name":"Medical Marketing Department, Burning Rock Biotech","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Marketing Department, Burning Rock Biotech","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheukfai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiaopei","family":"Mok","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhu","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.Cd-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discovery"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.18632\/aging.102783","article-title":"Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer","volume":"12","author":"Chen","year":"","journal-title":"Aging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1530\/erc-19-0414","article-title":"Heterogeneity of genomic profile in patients with HER2-positive breast cancer","volume":"27","author":"Chen","year":"","journal-title":"Endocr. Relat. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1158\/1078-0432.Ccr-24-0459","article-title":"An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in patients with breast cancer from four prospective clinical trials","volume":"30","author":"Jank","year":"2024","journal-title":"Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann. Oncology Official Journal Eur. Soc. Med. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4143\/crt.2022.221","article-title":"PIK3CA mutation is associated with poor response to HER2-Targeted therapy in breast cancer patients","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Research Treatment"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/s1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.3390\/biomedicines11123164","article-title":"Integrated molecular characterization of HER2-Low breast cancer using next generation sequencing (NGS)","volume":"11","author":"Merlin","year":"2023","journal-title":"Biomedicines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.Ccr-18-2867","article-title":"Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12935-022-02761-1","article-title":"HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry","volume":"22","author":"Morsberger","year":"2022","journal-title":"Cancer Cell International"},{"key":"B13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1158\/0008-5472.Can-19-1991","article-title":"Rare BRIP1 missense alleles confer risk for ovarian and breast cancer","volume":"80","author":"Moyer","year":"2020","journal-title":"Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/gcc.22431","article-title":"Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance","volume":"56","author":"Pfarr","year":"2017","journal-title":"Genes, Chromosomes and Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J. Molecular Diagnostics JMD"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2400365","DOI":"10.1200\/go-24-00365","article-title":"Retrospective study to determine factors influencing outcome in patients with human epidermal growth factor receptor 2-Positive breast cancer receiving neoadjuvant chemotherapy","volume":"11","author":"Shah","year":"2025","journal-title":"JCO Global Oncology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer Journal Clinicians"},{"key":"B18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s1470-2045(19)30097-x","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.5858\/arpa.2015-0133-RA","article-title":"Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update","volume":"140","author":"Tang","year":"2016","journal-title":"Archives Pathology and Laboratory Medicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.pathol.2023.10.011","article-title":"Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers","volume":"56","author":"Tay","year":"2024","journal-title":"Pathology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/s1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/jco.2006.09.2775","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/jco.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/jco.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1007\/s12032-012-0242-8","article-title":"Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab\/taxanes but not disease-free survival in HER2-positive breast cancer patients","volume":"29","author":"Zhang","year":"2012","journal-title":"Med. Oncology N. Lond. Engl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.21037\/atm.2019.04.23","article-title":"Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann. Translational Medicine"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1873228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:29:35Z","timestamp":1782188975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1873228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":28,"alternative-id":["10.3389\/fmolb.2026.1873228"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1873228","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1873228"}}